Pepric Appoints Dr. Enrico Bastianelli as Independent Director
News May 27, 2015
The General Assembly of Pepric has appointed Dr. Enrico Bastianelli as independent non-executive Board member. Dr. Bastianelli is the CEO of Bone Therapeutics since 2006, a cell therapy company for bone fracture repair and prevention.
Previously, Dr. Bastianelli gained a tremendous expertise in the cell and pharmaceutical industry based on many years of experience at Procter and Gamble Pharmaceuticals, McKinsey & Co and ProSkelia.
“We are delighted to welcome Dr. Bastianelli to the Board of Pepric, developing instrumentation for cell and particle detection and imaging. His experience and profound understanding of the end-users market of Pepric’s technology will deliver substantial benefit in the decision making process.”, said Stephanie Teughels, CEO of Pepric.
Commenting on his appointment, Dr. Bastianelli said: “I’m pleased to join Pepric offering new solutions for targeted molecular imaging and longitudinal cell detection. I’m looking forward to contribute to its business strategy to maximize the potential of its innovative instruments.”
Prime Oyster Area Has Worryingly High Concentrations of MicroplasticsNews
BC’s premier shellfish farming region is heavily contaminated with microplastics, according to a new study. The findings show action is required to reduce the environmental impact and entry to the food chain.READ MORE
Nanomaterials Help Great Works of ArtNews
It turns out that works of art might be their own worst enemy — the canvases they were painted on can deteriorate over time. In an effort to combat this aging process, one group report that nanomaterials can provide multiple layers of reinforcement.READ MORE